Michal Uher
0000-0001-8970-5928
17 papers found
Refreshing results…
Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation
Prognostic survival factors of hepatocellular carcinoma treated with transarterial chemoembolization,Prognostické faktory přežití u pacientů s hepatocelulárním karcinomem léčených pomocí transarteriální chemoembolizace
Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: Analysis of Czech ATTRA ankylosing spondylitis biologic registry
Vitamin d supplementation dose needs to be higher in patients with inflammatory bowel disease: Interventional study,U nemocných s idiopatickými střevními záněty je potřeba vitaminu d vyšší: Intervenční studie
Chemoembolization for treatment of hepatocellular carcinoma-National Registry-Based analysis,Chemoembolizace hepatocelulárního karcinomu-analýza výsledků léčby na základě dat z národních registrů
Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study
Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes
The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis – a cohort study
Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration
Idiopathic pulmonary fibrosis prognostic factors - Analysis of the Czech registry,Prognostické faktory idiopatické plicní fibrózy (IPF) - Analýza českého registru IPF
Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: A cohort study
First experience with biosimilar infliximab CT-P13 in patipntc with inflammatory rhpumatir riteoacpc in the Czech Republic in the ATTRA national registry,První zkušenosti s biosimilárním infliximabem CT-P13 u nemocných se zánětlivými revmatickými onemocneními v České republice v národním registru ATTRA
A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study
On the Importance of Standardization in the Assessment of Population-based Cancer Patient Survival in the Czech Republic – Methodology and Results from the Czech National Cancer Registry
Assessment of utility score EQ-D and estimating the Cost-utility of the first year of treatment by TNF inhibitors in a cohort of patients with Rheumatoid Arthritis during-results from the Czech biologics registry ATTRA,Hodnocení skóre užitku EQ-5D a odhad nákladové užitečnosti prvního roku léčby inhibitory TNF u pacientů s revmatoidní artritidou - Výsledky analýzy z národního registru biologické léčby ATTRA
Health related quality of life in patients with rheumatoid arthritis during the first year of treatment by TNF inhibitors (assessed by SF-36 questionnaire and compared with a sample of general Czech population),Zdravím podmíněná kvalita života u pacientů s revmatoidní artritidou v průběhu prvního roku anti-TNF léčby (hodnocení
Ranibizumab in the ARMD wet form treatment - Two years results obtained from the AMADEuS registry,Ranibizumab v léčbě vlhké formy VPMD - dvouleté výsledky léčby z registru AMADEuS
Missing publications? Search for publications with a matching author name.